Will GLP-1s Work for You? Predicting Response
Response varies widely. What the research says about who loses the most — and why.
Average weight-loss figures for GLP-1 drugs hide an uncomfortable truth: the average is built from a wide spread. In the major trials, some participants lost a large fraction of their body weight while others lost relatively little on the same medication and dose. If you are considering one of these drugs, the honest version of “will it work?” is really “where might I land in that distribution?” — and the science can narrow the guess only partway.
What variation looks like
In trials of semaglutide and tirzepatide, mean weight loss is substantial, but the individual results scatter around it. A meaningful minority are sometimes classified as “low responders,” losing far less than the headline number. This is normal for any drug acting on complex biology — but it gets flattened in the marketing.
Signals that correlate with response
Researchers have looked hard for predictors. The picture is suggestive rather than precise:
- Early response tends to forecast later response. People who lose a noticeable amount in the first months are, on average, more likely to do well by the end. This is one of the more consistent findings.
- Adherence and tolerability. Side effects that lead to dose reduction or stopping naturally blunt results. Staying on an effective dose matters.
- The drug and dose themselves. On average, the dual-agonist tirzepatide has produced larger losses than semaglutide in head-to-head and cross-trial comparisons, though individuals still vary.
- Behavioral context. Diet quality, sleep, and activity don’t disappear as factors just because a drug is involved.
The most reliable single predictor we have is your own early response — not a genetic test or a body type. The first few months are informative in a way that pre-treatment guessing is not.
What doesn’t predict well
It is worth saying plainly what we can’t do confidently yet. There is no validated, widely available test that tells an individual in advance whether they will be a strong or weak responder. Research into genetic and biomarker predictors is active and interesting, but it has not produced a clinical tool you should be paying for today.
A practical way to think about it
Because early response is the best available signal, a sensible framing is to treat the first stretch of treatment as the test. If, after giving the drug a fair trial at an appropriate dose, the response is genuinely minimal, that is real information — sometimes a reason to switch agents or reassess, made together with a clinician.
The takeaway
GLP-1s work well for many people and underwhelm for some, and we cannot yet tell which group you’re in before you start. The most honest answer is empirical: give it a proper, supervised trial, watch the early trajectory, and let your own response — not an average from a press release — set your expectations.
This is sample content created during site scaffolding. Replace with reviewed, fully-cited editorial before launch.